539871 Stock Overview Provides diagnostic testing services to patients, laboratories, and hospitals in India. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Thyrocare Technologies Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Thyrocare Technologies Historical stock prices Current Share Price ₹948.85 52 Week High ₹1,050.65 52 Week Low ₹555.85 Beta 0.45 1 Month Change -0.90% 3 Month Change 11.46% 1 Year Change 40.49% 3 Year Change -6.28% 5 Year Change 75.15% Change since IPO 53.54%
Recent News & Updates
MD, CEO & Chairman recently bought ₹1.1m worth of stock Nov 07
Price target increased by 9.1% to ₹903 Oct 24
Second quarter 2025 earnings released: EPS: ₹4.99 (vs ₹3.84 in 2Q 2024) Oct 24
High number of new directors Oct 18
Thyrocare Technologies Limited to Report Q2, 2025 Results on Oct 23, 2024 Oct 16
Now 23% overvalued after recent price rise Oct 16 See more updates
MD, CEO & Chairman recently bought ₹1.1m worth of stock Nov 07
Price target increased by 9.1% to ₹903 Oct 24
Second quarter 2025 earnings released: EPS: ₹4.99 (vs ₹3.84 in 2Q 2024) Oct 24
High number of new directors Oct 18
Thyrocare Technologies Limited to Report Q2, 2025 Results on Oct 23, 2024 Oct 16
Now 23% overvalued after recent price rise Oct 16
Price target increased by 8.5% to ₹828 Oct 12
Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million. Oct 11 Thyrocare Technologies Limited Announces Cessation of Mr. Neetin Shivajirao Desai as Independent Director as Well as Member of the Respective Committee(s) of the Board
Now 20% overvalued after recent price rise Sep 03
Thyrocare Technologies Limited Approves Dividend for the Financial Year 2023-24 Aug 27
Thyrocare Technologies Limited Announces Cessation of Gopalkrishna Shivaram Hegde as Independent Director and as Member / Chairman of the Respective Committee Aug 21
Now 20% overvalued after recent price rise Aug 13
Upcoming dividend of ₹18.00 per share Aug 09
Thyrocare Technologies Limited, Annual General Meeting, Aug 23, 2024 Aug 02
Consensus EPS estimates increase by 11% Jul 30
Thyrocare Technologies Limited (BSE:539871) acquired Diagnostic and pathological services business of Polo Labs Private Limited for INR 42.6 million. Jul 30
Price target increased by 8.1% to ₹800 Jul 24
Now 23% overvalued after recent price rise Jul 24
First quarter 2025 earnings released: EPS: ₹4.52 (vs ₹3.26 in 1Q 2024) Jul 24
Thyrocare Technologies Limited to Report Q1, 2025 Results on Jul 23, 2024 Jul 17
Now 23% overvalued after recent price rise Jun 12
Thyrocare Technologies Limited Proposes Final Dividend for the Financial Year 2023-24 May 15
Thyrocare Technologies Limited to Report Q4, 2024 Results on May 14, 2024 May 09
Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Think Health Diagnostic Private Limited. Feb 28
High number of new directors Feb 22
Third quarter 2024 earnings released: EPS: ₹2.78 (vs ₹1.89 in 3Q 2023) Feb 02
Thyrocare Technologies Limited to Report Q3, 2024 Results on Feb 01, 2024 Jan 25
Price target increased by 7.3% to ₹695 Dec 13
Second quarter 2024 earnings released: EPS: ₹3.84 (vs ₹3.80 in 2Q 2023) Nov 02
Thyrocare Technologies Limited to Report Q2, 2024 Results on Oct 31, 2023 Oct 24
MD, CEO & Chairman recently bought ₹4.3m worth of stock Aug 18
Thyrocare Technologies Limited Appoints Alok Kumar Jagnani as Chief Financial Officer Aug 03
Price target decreased by 18% to ₹643 Aug 02
High number of new directors Aug 01
Thyrocare Technologies Limited to Report Q1, 2024 Results on Aug 01, 2023 Jul 28
Full year 2023 earnings: EPS and revenues miss analyst expectations Jul 21
Thyrocare Technologies Limited Accepts Resignation of Sachin Salvi as Chief Financial Officer Jul 15
Consensus EPS estimates fall by 27% Jul 13
Full year 2023 earnings: EPS and revenues miss analyst expectations May 24
Thyrocare Technologies Limited to Report Q4, 2023 Results on May 23, 2023 May 17
Thyrocare Technologies Limited Announces Resignation of Vishwas Kulkarni as an Independent Director May 10
Upcoming dividend of ₹18.00 per share at 3.1% yield Apr 13
MD, CEO & Director recently bought ₹10m worth of stock Feb 12
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Feb 05
Thyrocare Technologies Limited to Report Q3, 2023 Results on Feb 03, 2023 Jan 18
Consensus EPS estimates fall by 19% Nov 18
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 16
Thyrocare Technologies Limited (BSE:539871) agreed to acquire 51% stake in Pulse Hitech Health Services (Ghatkopar) LLP for INR 25.5 million. Nov 14
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 13
Thyrocare Technologies Limited to Report Q2, 2023 Results on Nov 11, 2022 Nov 03
MD, CEO & Director recently bought ₹16m worth of stock Aug 11
Consensus EPS estimates fall by 12% Aug 08
Thyrocare Technologies Limited Announces Payment of Interim Dividend for the Financial Year 2021-2022 Aug 06
Full year 2022 earnings: EPS and revenues miss analyst expectations Jul 14
Thyrocare Technologies Limited, Annual General Meeting, Aug 03, 2022 Jul 13
Price target decreased to ₹1,073 May 10
Consensus forecasts updated May 06 Thyrocare Technologies Limited Joins Rahul Guha as Managing Director
Thyrocare Technologies Limited Declares Interim Dividend for the Financial Year 2021-22 May 02
Full year 2022 earnings: EPS and revenues miss analyst expectations May 01
Thyrocare Technologies Limited to Report Q4, 2022 Results on Apr 29, 2022 Apr 23
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Feb 13 Thyrocare Technologies Limited Announces Appointment of Rahul Guha as Managing Director
Thyrocare Technologies Limited Appoints Sachin Salvi as Chief Financial Officer Jan 30
First quarter 2022 earnings released: EPS ₹10.51 (vs ₹0.04 in 1Q 2021) Nov 01
Consensus forecasts updated Aug 19
First quarter 2022 earnings released: EPS ₹10.51 (vs ₹0.04 in 1Q 2021) Aug 13
Price target increased to ₹1,233 Jun 30
Docon Technologies Private Limited entered into a share purchase agreement to acquire 66.11% stake in Thyrocare Technologies Limited (BSE:539871) from a group of shareholders for INR 45.5 billion. Jun 26
Pharmeasy Looks to Acquire a Stake in Thyrocare Jun 18
Investor sentiment improved over the past week Jun 11
Upcoming dividend of ₹15.00 per share Jun 11
Full year 2021 earnings released: EPS ₹21.41 (vs ₹16.74 in FY 2020) Jun 09
Full year 2021 earnings released: EPS ₹21.41 (vs ₹16.74 in FY 2020) May 13
Investor sentiment improved over the past week Apr 06
New 90-day low: ₹868 Mar 15
Analysts lower EPS estimates to ₹20.97 Feb 06
Third quarter 2021 earnings released: EPS ₹6.13 (vs ₹5.21 in 3Q 2020) Feb 01
Revenue and earnings miss expectations Feb 01
New 90-day low: ₹903 Jan 30
Thyrocare Technologies Limited to Report Q3, 2021 Results on Jan 30, 2021 Jan 23
Chairman & MD recently bought ₹6.3m worth of stock Dec 24
Upcoming Dividend of ₹10.00 Per Share Nov 05
Analysts increase revenue estimates to ₹5.34b Nov 04
First half earnings released Oct 30
Second-quarter earnings released: Revenue misses expectations Oct 30
New 90-day high: ₹1,136 Oct 26
Price target raised to ₹775 Oct 23
Chairman recently bought ₹20m worth of stock Oct 07
New 90-day high: ₹884 Oct 06
Chairman recently bought ₹6.3m worth of stock Sep 11
Chairman recently bought ₹9.6m worth of stock Aug 19 Shareholder Returns 539871 IN Healthcare IN Market 7D -3.8% -1.3% -4.3% 1Y 40.5% 41.8% 19.1%
See full shareholder returns
Return vs Market: 539871 exceeded the Indian Market which returned 19.1% over the past year.
Price Volatility Is 539871's price volatile compared to industry and market? 539871 volatility 539871 Average Weekly Movement 5.0% Healthcare Industry Average Movement 5.6% Market Average Movement 6.2% 10% most volatile stocks in IN Market 9.0% 10% least volatile stocks in IN Market 4.1%
Stable Share Price: 539871 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 539871's weekly volatility (5%) has been stable over the past year.
About the Company Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The company conducts various medical diagnostic tests and profiles of tests that focuses on early detection and management of disorders and diseases, including thyroid, growth, metabolism, auto-immunity, diabetes, anaemia, cardiovascular, infertility, and various infectious diseases.
Show more Thyrocare Technologies Limited Fundamentals Summary How do Thyrocare Technologies's earnings and revenue compare to its market cap? 539871 fundamental statistics Market cap ₹50.24b Earnings (TTM ) ₹839.60m Revenue (TTM ) ₹6.23b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 539871 income statement (TTM ) Revenue ₹6.23b Cost of Revenue ₹3.14b Gross Profit ₹3.09b Other Expenses ₹2.25b Earnings ₹839.60m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 15.86 Gross Margin 49.55% Net Profit Margin 13.47% Debt/Equity Ratio 0.02%
How did 539871 perform over the long term?
See historical performance and comparison Dividends
1.9% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 03:14 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Thyrocare Technologies Limited is covered by 12 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Alka Katiyar Batlivala & Karani Securities India Pvt. Ltd. Rahul Agarwal CGS International Kameswari V. S. Chavali FirstCall Research
Show 9 more analysts 
